Significant Decline in HCV ‐Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015–2022): A Sentinel Center Study
Liver International · 2025
DOI: 10.1111/liv.70388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Cheng-Yeh Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Promotion Administration, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
Reducing mortality attributable to hepatitis C virus (HCV) is a key target in the World Health Organization (WHO) HCV elimination strategy. While liver cancer registration in Taiwan includes hepatitis C antibody (anti‐HCV) status, no national registry records viral etiologies for deaths from liver cirrhosis and chronic liver disease (LC/CLD). Therefore, this sentinel study aimed to estimate national trends in HCV‐related LC/CLD mortality.
Methods
The study period spanned from 2015 to 2022. According to ICD‐10 codes K70, K73 and K74, the annual mortality numbers for LC/CLD were extracted from national biostatistics. Using the Chang Gung Research Database (CGRD), cases that died from LC/CLD with available results for both HBsAg and anti‐HCV tests were included in the analysis. Based on the proportions of HCV distributions from CGRD, the national viral etiology‐specific case numbers were estimated using a direct standardised method.
Results
A total of 35 413 patients died from LC/CLD nationally, with 15 445 of them having medical records in CGRD, and 5940 (16.8%) having results for both HBsAg and anti‐HCV tests. The national case number was 4878 in 2015, decreasing to 4107 (−15.8%) in 2022. The proportion of anti‐HCV decreased from 25.7% to 16.6% (−36.2%). Direct standardisation showed that the estimated national case number for anti‐HCV decreased from 1424 to 811 (−43%).
Conclusions
From 2015 to 2022, Taiwan experienced a 43% decline in HCV‐related LC/CLD mortality, supporting progress toward national HCV elimination goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Biostatistics Center of Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Division of Hepato-Gastroenterology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
ORCID-Profile: Cheng-Yeh Yang, Jing-Houng Wang, Rong-Nan Chien, Sheng-Nan Lu
Förderung
- Health Promotion Administration, Ministry of Health and Welfare
Zitieren
APA
Yang, C. Y., Lin, C. Y., Wang, J. H., Lin, C. Y., Chien, R. N., & Lu, S. N. (2025). Significant Decline in HCV ‐Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015–2022): A Sentinel Center Study. Liver International. https://doi.org/10.1111/liv.70388
Vancouver
Yang CY, Lin CY, Wang JH, Lin CY, Chien RN, Lu SN. Significant Decline in HCV ‐Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015–2022): A Sentinel Center Study. Liver International. 2025. doi:10.1111/liv.70388
BibTeX
@article{Yang2025,
author = {Yang, Cheng-Yeh and Lin, Chih-Yun and Wang, Jing-Houng and Lin, Chun-Yen and Chien, Rong-Nan and Lu, Sheng-Nan},
title = {Significant Decline in HCV ‐Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015–2022): A Sentinel Center Study},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70388}
}
EUVIMED